专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US07928128B2 Use of(R)-(−) -2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane and its physiologically acceptable salts 有权
标题翻译：（R） - （ - ） - 2- [5-（4-氟苯基）-3-吡啶甲基氨基甲基] - 苯并二氢吡喃及其生理学上可接受的盐
公开(公告)号：US07928128B2
公开(公告)日：2011-04-19
申请号：US10221031
申请日：2001-02-01
申请人： Gerd Bartoszyk , Hermann Russ , Christoph Seyfried , Frank Weber
发明人： Gerd Bartoszyk , Hermann Russ , Christoph Seyfried , Frank Weber
IPC分类号： A61K31/44 , A61K31/35
CPC分类号： A61K31/353 , A61K31/4433 , A61K45/06 , A61K2300/00
摘要： (R)-(−)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane or a physiologically acceptable salt thereof is useful for treatment of adverse effects in treating Parkinson's disease.
摘要翻译：（R） - （ - ） - 2- [5-（4-氟苯基）-3-吡啶甲基氨基甲基] - 苯并二氢吡喃或其生理学上可接受的盐可用于治疗帕金森病的不良反应。

2. 发明授权

US07642261B2 Use of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine and its physiologically acceptable salts 有权
标题翻译： 1- [4-（5-氰基吲哚-3-基）丁基] -4-（2-氨基甲酰基 - 苯并呋喃-5-基） - 哌嗪及其生理上可接受的盐
公开(公告)号：US07642261B2
公开(公告)日：2010-01-05
申请号：US11946149
申请日：2007-11-28
申请人： Gerd Bartoszyk , Christoph Seyfried , Christoph Von Amsterdam , Henning Boettcher , Ewen Sedman
发明人： Gerd Bartoszyk , Christoph Seyfried , Christoph Von Amsterdam , Henning Boettcher , Ewen Sedman
IPC分类号： A61K31/497
CPC分类号： A61K31/496 , A61K31/00 , A61K31/495 , A61K31/497
摘要： 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine or a physiologically acceptable salt thereof is used for the manufacture of a medicament for the treatment of sub-type anxiety disorders chosen from the sub-types panic disorder with or without agoraphobia, agoraphobia obsessive-compulsive spectrum disorders, social phobia, posttraumatic stress disorder, acute stress indication or generalized-anxiety disorder, bipolar disorders, mania, dementia substance-related disorders, sexual dysfunctions, eating disorders, obesity, anorexia and fibromyalgia. A preferred salt is 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine hydrochloride.
摘要翻译： 1- [4-（5-氰基吲哚-3-基）丁基] -4-（2-氨基甲酰基 - 苯并呋喃-5-基） - 哌嗪或其生理学上可接受的盐用于制备用于治疗亚型类焦虑障碍选自亚急性恐惧症，有或没有广场恐怖症，广场恐惧症强迫症频谱障碍，社会恐惧症，创伤后应激障碍，急性应激指征或全身焦虑症，双相性精神障碍，躁狂症，痴呆症相关疾病，性功能障碍，饮食失调，肥胖，厌食和纤维肌痛。优选的盐是1- [4-（5-氰基吲哚-3-基）丁基] -4-（2-氨基甲酰基 - 苯并呋喃-5-基） - 哌嗪盐酸盐。

3. 发明授权

US07385065B2 Derivatives of asimadoline with covalently bonded acids 有权
标题翻译：具有共价键的酸的阿莫达林的衍生物
公开(公告)号：US07385065B2
公开(公告)日：2008-06-10
申请号：US10539256
申请日：2003-11-25
申请人： Matthias Wiesner , Christoph Seyfried
发明人： Matthias Wiesner , Christoph Seyfried
IPC分类号： C07D207/12
CPC分类号： C07D207/12
摘要： The present invention relates to derivatives of N-methyl-N-[(1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)ethyl]-2,2-diphenylacetamide with covalently bonded acids, and to the salts, solvates and prodrugs thereof, to the derivatives as medicaments, to the use of these derivatives for the preparation of a medicament, to the use of these derivatives for the preparation of a pharmaceutical composition, to a process for the preparation of the pharmaceutical compositions, to pharmaceutical compositions obtainable by this process, and to a process for the treatment of diseases which comprises the administration of the pharmaceutical composition.
摘要翻译：本发明涉及具有共价键的酸的N-甲基-N - [（1S）-1-苯基-2 - （（3S）-3-羟基吡咯烷-1-基）乙基] -2,2-二苯基乙酰胺的衍生物，以及其盐，溶剂合物和前药，作为药物的衍生物，使用这些衍生物用于制备药物，将这些衍生物用于制备药物组合物的方法，用于制备药物组合物，可通过该方法获得的药物组合物，以及用于治疗包括施用药物组合物的疾病的方法。

4. 发明申请

US20080027140A1 Combinations of Serotonin Reuptake Inhibitors and Imidazoline I 2 Agonists 审中-公开
标题翻译： 5-羟色胺再摄取抑制剂和咪唑啉I 2激动剂的组合
公开(公告)号：US20080027140A1
公开(公告)日：2008-01-31
申请号：US10586457
申请日：2004-12-15
申请人： Gerd Bartoszyk , Christoph Van Amsterdam , Henning Boettcher , Christoph Seyfried
发明人： Gerd Bartoszyk , Christoph Van Amsterdam , Henning Boettcher , Christoph Seyfried
IPC分类号： A61K31/135 , A61P25/00
CPC分类号： A61K45/06 , A61K31/138 , A61K31/4178 , A61K2300/00
摘要： The present invention relates to combinations of serotonin reuptake inhibitors and imidazoline I2 agonists as separate chemical units or both properties combined in a single molecule and to the use thereof for the preparation of medicaments for the treatment of depression, obsessive-compulsive disorders (OCDs), obsessive-compulsive spectrum disorders (OCSDs) and other anxiety states.
摘要翻译：本发明涉及作为分开的化学单元的5-羟色胺再摄取抑制剂和咪唑啉I 2激动剂的组合，或者在单个分子中组合的两种性质以及用于制备用于治疗抑郁症的药物的用途，强迫症（强迫症），强迫症频谱障碍（OCSD）和其他焦虑症状。

5. 发明申请

US20060167078A1 Substituted benzodioxepins 失效
标题翻译：取代苯并二氧杂环庚烯
公开(公告)号：US20060167078A1
公开(公告)日：2006-07-27
申请号：US10539515
申请日：2003-11-27
申请人： Timo Heinrich , Henning Boettcher , Kai Schiemann , Geunter Holzemann , Christoph van Amsterdam , Gerd Bartoszyk , Hartmut Greiner , Christoph Seyfried , Michel Brunet , Jean Zeiller , Jean Berthelon
发明人： Timo Heinrich , Henning Boettcher , Kai Schiemann , Geunter Holzemann , Christoph van Amsterdam , Gerd Bartoszyk , Hartmut Greiner , Christoph Seyfried , Michel Brunet , Jean Zeiller , Jean Berthelon
IPC分类号： A61K31/405 , C07D407/02
CPC分类号： C07D405/12
摘要： Benzodioxepines of the formula (I) and physiologically tolerated salts and solvates thereof, in which R1, R2, R3, R4, A, B, a and b have the meanings indicated in claim 1, are ligands of the 5HT1A receptors and/or the 5HT4 receptors with simultaneously strong serotonin reuptake inhibition. They can be employed for the treatment and prophylaxis of various diseases.
摘要翻译：式（I）的苯并二氧杂环庚烷及其生理上耐受的盐和溶剂合物，其中R 1，R 2，R 3，R SUP > 4，A，B，a和b具有权利要求1中所示的含义，是具有同时强烈的5-羟色胺再摄取抑制的5HT1A受体和/或5HT4受体的配体。可用于治疗和预防各种疾病。

6. 发明申请

US20060116405A1 Indol derivatives and their use as 5-ht ligands 失效
标题翻译：吲哚衍生物及其作为5-ht配体的用途
公开(公告)号：US20060116405A1
公开(公告)日：2006-06-01
申请号：US10538639
申请日：2003-11-17
申请人： Gunter Hoelzemann , Helene Crassier , Henning Bottcher , Timo Heinrich , Kai Schiemann , Joachim Leibrock , Chrisoph Van Amsterdam , Gerd Bartoszyk , Christoph Seyfried
发明人： Gunter Hoelzemann , Helene Crassier , Henning Bottcher , Timo Heinrich , Kai Schiemann , Joachim Leibrock , Chrisoph Van Amsterdam , Gerd Bartoszyk , Christoph Seyfried
IPC分类号： A61K31/433 , A61K31/4245 , C07D417/02 , C07D413/02
CPC分类号： C07D413/12 , C07D417/12
摘要： The invention relates to indol derivatives of Formula (I) in which R1, R2, R3, X, A, n, m and p have the meanings indicated above.
摘要翻译：本发明涉及式（I）的吲哚衍生物，其中R 1，R 2，R 3，X，A，n，m和p具有上述含义。

7. 发明授权

US06900212B1 Use of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine and its physiologically acceptable salts 有权
标题翻译： 1- [4-（5-氰基吲哚-3-基）丁基] -4-（2-氨基甲酰基 - 苯并呋喃-5-基） - 哌嗪及其生理上可接受的盐
公开(公告)号：US06900212B1
公开(公告)日：2005-05-31
申请号：US09979922
申请日：2000-05-16
申请人： Gerd Bartoszyk , Christoph Seyfried , Christoph Von Amsterdam , Henning Boettcher , Ewen Sedman
发明人： Gerd Bartoszyk , Christoph Seyfried , Christoph Von Amsterdam , Henning Boettcher , Ewen Sedman
IPC分类号： C07D405/12 , A61K31/00 , A61K31/495 , A61K31/496 , A61P1/14 , A61P3/04 , A61P15/10 , A61P21/00 , A61P25/00 , A61P25/22 , A61P25/28 , A61P29/00 , A61K31/50
CPC分类号： A61K31/496 , A61K31/00 , A61K31/495 , A61K31/497
摘要： 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine or a physiologically acceptable salt thereof, for the treatment of sub-type anxiety disorders chosen from the sub-types: panic disorder with or without agoraphobia, agoraphobia, obsessive-compulsive spectrum disorders, social phobia, posttraumatic stress disorder, acute stress indication or generalized anxiety disorder, bipolar disorders, mania, dementia, substance-related disorders, sexual dysfunctions, eating disorders, obesity, anorexia, and fibromyalgia. A preferred salts is 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine hydrochloride.
摘要翻译： 1- [4-（5-氰基吲哚-3-基）丁基] -4-（2-氨基甲酰基 - 苯并呋喃-5-基） - 哌嗪或其生理上可接受的盐，用于治疗选自以下的亚型焦虑症子类型：伴有或不伴有恐惧症的恐慌症，广场恐惧症，强迫症频谱障碍，社交恐惧症，创伤后应激障碍，急性应激指征或广泛性焦虑症，双相情感障碍，躁狂症，痴呆，物质相关疾病，性功能障碍，饮食失调，肥胖，厌食和纤维肌痛。优选的盐是1- [4-（5-氰基吲哚-3-基）丁基] -4-（2-氨基甲酰基 - 苯并呋喃-5-基） - 哌嗪盐酸盐。

8. 发明授权

US06756370B1 Piperidine alcohols 失效
标题翻译：哌啶醇
公开(公告)号：US06756370B1
公开(公告)日：2004-06-29
申请号：US10069054
申请日：2002-02-21
申请人： Helmut Prücher , Henning Böttcher , Karl-August Ackermann , Rudolf Gottschlich , Christoph van Amsterdam , Christoph Seyfried , Jürgen Harting , Gerd Bartoszyk , Hartmut Greiner
发明人： Helmut Prücher , Henning Böttcher , Karl-August Ackermann , Rudolf Gottschlich , Christoph van Amsterdam , Christoph Seyfried , Jürgen Harting , Gerd Bartoszyk , Hartmut Greiner
IPC分类号： A61K3154
CPC分类号： C07D401/06 , C07D211/22 , C07D405/06 , C07D409/06 , C07D417/06
摘要： The invention relates to compounds of formula (I), wherein R1, R2 and A have the meanings given in claim 1, are potent 5-HT2A antagonists and are suitable for treating psychoses, schizophrenia, depression, neurological disorders, impaired memory, Parkinson's disease, amyotrophic lateral sclerosis, Alzheimer's disease, Huntington's disease, eating disorders such as bulimia and anorexia nervosa, Pre-Menstrual Syndrome and/or for positively influencing obsessive-compulsive disorders, (OCD).
摘要翻译：本发明涉及式（I）化合物，其中R 1，R 2和A具有权利要求1中给出的含义，它们是有效的5-HT2A拮抗剂，适用于治疗精神病，精神分裂症，抑郁症，神经障碍记忆障碍，帕金森病，肌萎缩性侧索硬化症，阿尔茨海默氏病，亨廷顿疾病，进食障碍如贪食症和神经性厌食症，前月经综合征和/或积极影响强迫症（OCD）。

9. 发明授权

US06258813B1 D4 receptor selectivity piperazine derivatives 失效
标题翻译： D4受体选择性哌嗪衍生物
公开(公告)号：US06258813B1
公开(公告)日：2001-07-10
申请号：US09254489
申请日：1999-03-09
申请人： Michael Arlt , Henning Bottcher , Gerd Bartoszyk , Christoph Seyfried
发明人： Michael Arlt , Henning Bottcher , Gerd Bartoszyk , Christoph Seyfried
IPC分类号： A61K31496
CPC分类号： C07D213/74 , C07D213/38 , C07D239/42 , C07D295/073 , C07D295/096 , C07D295/155 , C07D401/12 , C07D405/12 , C07D409/12
摘要： Piperazine derivatives of the formula I in which R1 and R2 have the meanings given in claim 1 are dopamine ligands with a selectivity for the D4 receptor and are suitable for the treatment and prophylaxis of states of anxiety, depression, schizophrenia, obsessions, Parkinson's disease, tardive dyskinesia, nausea and disorders of the gastro-intestinal tract.
摘要翻译： R1和R2具有权利要求1中给出的含义的式Iin的哌嗪衍生物是对D4受体具有选择性的多巴胺配体，并且适用于治疗和预防焦虑，抑郁，精神分裂症，痴呆，帕金森病，迟发性运动障碍，恶心和胃肠道疾病。

10. 发明授权

US5977161A Kappa-opiate agonists effective in the treatment of postoperative ileus 失效
标题翻译：卡帕阿片激动剂有效治疗术后肠梗阻
公开(公告)号：US5977161A
公开(公告)日：1999-11-02
申请号：US27228
申请日：1998-02-20
申请人： Andrew Barber , Christoph Seyfried , Gerd Bartoszyk , Rudolf Gottschlich
发明人： Andrew Barber , Christoph Seyfried , Gerd Bartoszyk , Rudolf Gottschlich
IPC分类号： C07D207/08 , A61K31/135 , A61K31/165 , A61K31/40 , A61K31/4015 , A61K31/4025 , A61P1/00 , A61P1/04 , A61P29/00 , A61P43/00 , C07D207/12
CPC分类号： A61K31/4025
摘要： Disclosed herein are pharmaceutical preparations which are suitable for the treatment of postoperative ileus and contain at least one compound of the formula I ##STR1## in which R.sup.1 is Ar, cycloalkyl having 3-7 C atoms or cycloalkylalkyl having 4-8 C atoms,R.sup.2 is Ar, orR.sub.1 and R.sup.2 together are ##STR2## R.sup.3 is H, OH, OA or A, R.sup.4 is A or phenyl which can optionally be mono- or disubstituted by Hal, OH, OA, CF.sub.3, NO.sub.2, NH.sub.2, NHA, NHCOA, NHSO.sub.2 A and/or NA.sub.2,R.sup.5 is OH, CH.sub.2 OH,R.sup.6 and R.sup.7 in each case independently of one another are H, Hal, OH, OA, CF.sub.3, NH.sub.2, NHA, NA.sub.2, NHCOA, NHCONH.sub.2, NO.sub.2 or methylenedioxy, with the oxy groups bonded to adjacent carbons on the ring,A is alkyl having 1-7 C atoms,Ar is a mono- or bicyclic aromatic radical which can optionally contain an N, O or S atom in the ring and can be mono-, di- or trisubstituted by A, Hal, OH, OA, CF.sub.3, NH.sub.2, NHA, NA.sub.2, NHCOA and/or NHCONH.sub.2,D is CH.sub.2, O, S, NH, NA, --CH.sub.2 --CH.sub.2 --, --CH.dbd.CH--, --CH.sub.2 NH--, --CH.sub.2 --NA-- or a bondandHal is F, Cl, Br or I.
摘要翻译：本文公开了适用于治疗术后肠梗阻并含有至少一种其中R 1为Ar的式I化合物或具有3-7个C原子的环烷基或具有4-8个C原子的环烷基烷基，R2为Ar，或R 1和R 2一起为R 3为H，OH，OA或A，R 4为A或可任选被Hal，OH，OA，CF 3，NO 2，NH 2，NHA，NHCOA，NHSO 2 A单取代或二取代的苯基和/或 NA2，R5分别为H，Hal，OH，OA，CF3，NH2，NHA，NA2，NHCOA，NHCONH2，NO2或亚甲二氧基的OH，CH2OH，R6和R7彼此独立地键合， A是具有1-7个C原子的烷基，Ar是可以在环中任选含有N，O或S原子的单环或双环芳族基团，并且可以被A，，Hal，OH，OA，CF 3，NH 2，NHA，NA 2，NHCOA和/或NHCONH 2，D是CH 2，O，S，NH，NA，-CH 2 -CH 2 - ， - CH = CH-， - CH 2 NH-， CH2-NA-或键，Hal为F，Cl，Br或I.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式